Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy.

Background: PCA3 has been included in a nomogram outperforming previous clinical models for the prediction of any prostate cancer (PCa) and high grade PCa (HGPCa) at the initial prostate biopsy (IBx). Our objective is to validate such IBx-specific PCA3-based nomogram. We also aim to optimize the use...

Descripción completa

Detalles Bibliográficos
Publicado en:BMC Cancer Vol. 15; no. 1; pp. 1 - 9
Autores principales: Rubio-Briones, Jose, Borque, Angel, Esteban, Luis M., Casanova, Juan, Fernandez-Serra, Antonio, Rubio, Luis, Casanova-Salas, Irene, Sanz, Gerardo, Domínguez-Escrig, Jose, Collado, Argimiro, Gómez-Ferrer, Alvaro, Iborra, Inmaculada, Ramírez-Backhaus, Miguel, Martínez, Francisco, Calatrava, Ana, Lopez-Guerrero, Jose A.
Formato: research tables/charts Journal Article
Publicado: BioMed Central 9/12/2015
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109517459&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 109517459
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        14712407
        1CH9
      jtl: BMC Cancer
      issn: 14712407
      maglogo: N
    pubinfo:
      dt: 9/12/2015
      vid: 15
      iid: 1
      pid: 24147
      pub: BioMed Central
    artinfo:
      ui:
        109517459
        109517459
        NLM26362197
        109517459
        10.1186/s12885-015-1623-0
        NLM26362197
        PMC4567811
        109517459
      ppf: 1
      ppct: 8
      formats:
      tig:
        atl: Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy.
      aug:
        au:
          Rubio-Briones, Jose
          Borque, Angel
          Esteban, Luis M.
          Casanova, Juan
          Fernandez-Serra, Antonio
          Rubio, Luis
          Casanova-Salas, Irene
          Sanz, Gerardo
          Domínguez-Escrig, Jose
          Collado, Argimiro
          Gómez-Ferrer, Alvaro
          Iborra, Inmaculada
          Ramírez-Backhaus, Miguel
          Martínez, Francisco
          Calatrava, Ana
          Lopez-Guerrero, Jose A.
        affil: Department of Urology, Instituto Valenciano de Oncología, C/Prof. Beltrán Báguena 8, 46009 Valencia, Spain
      sug:
        subj:
          Prostatic Neoplasms Metabolism
          Antigens, Tumor Metabolism
          Prostatic Neoplasms Diagnosis
          Risk Assessment Methods
          Models, Statistical
          Decision Support Techniques
          Aged
          Body Weights and Measures
          Biopsy
          Male
          Middle Age
          Prospective Studies
          Risk Factors
          Validation Studies
          Comparative Studies
          Evaluation Research
          Multicenter Studies
          Human
          Aged: 65+ years
          Middle Aged: 45-64 years
          Male
      ab: Background: PCA3 has been included in a nomogram outperforming previous clinical models for the prediction of any prostate cancer (PCa) and high grade PCa (HGPCa) at the initial prostate biopsy (IBx). Our objective is to validate such IBx-specific PCA3-based nomogram. We also aim to optimize the use of this nomogram in clinical practice through the definition of risk groups.Methods: Independent external validation. Clinical and biopsy data from a contemporary cohort of 401 men with the same inclusion criteria to those used to build up the reference's nomogram in IBx. The predictive value of the nomogram was assessed by means of calibration curves and discrimination ability through the area under the curve (AUC). Clinical utility of the nomogram was analyzed by choosing thresholds points that minimize the overlapping between probability density functions (PDF) in PCa and no PCa and HGPCa and no HGPCa groups, and net benefit was assessed by decision curves.Results: We detect 28% of PCa and 11 % of HGPCa in IBx, contrasting to the 46 and 20% at the reference series. Due to this, there is an overestimation of the nomogram probabilities shown in the calibration curve for PCa. The AUC values are 0.736 for PCa (C.I.95%:0.68-0.79) and 0.786 for HGPCa (C.I.95%:0.71-0.87) showing an adequate discrimination ability. PDF show differences in the distributions of nomogram probabilities in PCa and not PCa patient groups. A minimization of the overlapping between these curves confirms the threshold probability of harboring PCa >30 % proposed by Hansen is useful to indicate a IBx, but a cut-off > 40% could be better in series of opportunistic screening like ours. Similar results appear in HGPCa analysis. The decision curve also shows a net benefit of 6.31% for the threshold probability of 40%.Conclusions: PCA3 is an useful tool to select patients for IBx. Patients with a calculated probability of having PCa over 40% should be counseled to undergo an IBx if opportunistic screening is required.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N